Mar 9 2024 |
Oregon Prescription Drug Price Transparency Act in Limbo |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 11 2020 |
It’s Not Pop Secret, Ninth Circuit Affirms that Plaintiff Didn’t Have a Leg to Stand On |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 9 2010 |
EPA Proposes 'Veto' of Section 404 Permit for Mountaintop Removal Coal Mining Project in West Virginia |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 12 2011 |
California Court Issues Tentative Ruling Enjoining AB 32 Implementation |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 10 2018 |
Notes on Day 2 of the JP Morgan Healthcare Conference |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 8 2013 |
Governor Brown Signs Senate Bill 4 Regulating Hydraulic Fracturing Well Stimulation Treatments |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 17 2022 |
FDA Boosts Protein Preemption Defense |
Sheppard, Mullin, Richter & Hampton LLP |
Feb 11 2019 |
HHS Proposes Rule to Eliminate Safe Harbor for PBM Drug Rebates |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 21 2019 |
Federal Circuit Weighs in on Patent Subject-Matter Eligibility of Dietary Supplements |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 29 2022 |
California District Court Finds that EKRA Applies to Compensation Methodologies for Labs’ Employed Marketers Who Market to Physicians |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 6 2022 |
California Governor Signs into Law Cannabis Tax Relief Bill |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 21 2014 |
Faulty Damages Model Leads to Partial Decertification in California |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 27 2022 |
FDA Proposes Updated Rule for “Healthy” Foods |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 17 2020 |
FDA Grants COVID-19 Diagnostic Emergency Use Authorizations, And Other Recent FDA Actions to Address COVID-19 |
Sheppard, Mullin, Richter & Hampton LLP |
May 12 2020 |
“Happy Cows” False Labeling Theory is Just “Half Baked”: Court Dismisses False Advertising Claims Against Ben & Jerry’s |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 3 2024 |
FTC’s Campaign Against Improper Orange Book Listings Continues with Amicus Brief in Teva’s Challenge of Amneal Asthma Inhaler ANDA |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 14 2010 |
Elimination of Customs Duties Possible for Over 700 Additional Pharmaceutical Products and Chemical Intermediates |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 10 2018 |
WARNING: Prop 65 Has Changed – If Your Product Is Sold In California Or You Do Business In California, Pay Attention |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 19 2018 |
WARNING: There Are New Warning Requirements for Imports Sold in California |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 16 2021 |
Are Flavor Cases Fizzling? Two More Courts Grant Motions to Dismiss |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 12 2018 |
Brady v. Bayer Corp: One A Day Will Not Keep Plaintiffs Away |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 20 2018 |
Blog Series Part 7: CMS Proposed Rule on Policy and Technical Changes to the Medicare Advantage, Medicare Prescription Drug Benefit, Medicaid Fee-For-Service, and Medicaid Managed Care Programs for 2020 and 2021 |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 30 2022 |
Movement On CMRE Act and MORE Act On Capitol Hill |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 20 2022 |
FDA Issues Untitled Letter to Bausch Health Companies for Misleading Statements Relating to DUOBRII™ |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 19 2014 |
Supreme Court Rules Compliance with Food and Drug Administration (FDA) Labeling Guidelines Does Not Bar Lanham Act False Advertising Suits – POM Wonderful v. Coca-Cola Co. |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 21 2019 |
E-Cig Company Settles Online Behavioral Advertising Inquiry |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 29 2022 |
Time Is Not Always Money: Ninth Circuit Holds That Pre-Employment Drug Testing Is Not Compensable Under California Law |
Sheppard, Mullin, Richter & Hampton LLP |
Aug 8 2022 |
FDA Delays Enforcement of UDI Reporting Requirements for Consumer Health Products |
Sheppard, Mullin, Richter & Hampton LLP |
Aug 30 2022 |
Charging for Investigational Drugs Under an IND Questions and Answers, Draft Guidance for Industry, August 2022 |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 27 2014 |
J.M. Smucker Company Gets Out of a Jam in Food Labelling Case - Caldera v. The J.M. Smucker Co. |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 29 2019 |
CBO Report Shows Senate’s Bipartisan Bill on Surprise Billing, Drug Prices, Transparency, and More Would Result in Deficit Decrease |
Sheppard, Mullin, Richter & Hampton LLP |
Jun 14 2023 |
FDA Issues Proposed Rule for Standardized and Accessible Patient Medication Information |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 5 2016 |
Challenge to California Ordinance Prohibiting Mobile Medical Marijuana Dispensaries Goes Up in Smoke |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 7 2023 |
Context is Key: FDA Sends a Strong Message About Efficacy Claims |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 28 2023 |
A Second Chance to Win Your Government Healthcare Contract |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 2 2020 |
CMS Issues Temporary Waivers in Broad Coronavirus Response |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 23 2020 |
EEOC Updates Guidance To Permit Employer-Mandated COVID-19 Testing (US) |
Sheppard, Mullin, Richter & Hampton LLP |
Nov 8 2023 |
OIG General Compliance Program Guidance November 2023 |
Sheppard, Mullin, Richter & Hampton LLP |
May 1 2020 |
Where’s the Meat? Interim Federal Guidance for Meat Plant Worker Safety |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 21 2023 |
Pharmaceutical Companies Have Rights if the Federal Government Seized their Patents |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 25 2024 |
PFAS in Food Packaging: The Beginning of the End? |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 18 2020 |
The Next in the Series of Executive Orders Affecting the Pharmaceutical Industry |
Sheppard, Mullin, Richter & Hampton LLP |
Sep 30 2009 |
OTC Drug and Dietary Supplement Labeling: Adverse Event Reporting Information |
Sheppard, Mullin, Richter & Hampton LLP |
Jul 19 2018 |
340B Drug Pricing Program Litigation Update: American Hospital Association, Et Al. v. Azar |
Sheppard, Mullin, Richter & Hampton LLP |
Oct 25 2021 |
AB-45: California Finally Welcomes Hemp Products To The Marketplace |
Sheppard, Mullin, Richter & Hampton LLP |
Jan 7 2022 |
FDA Releases Guidance for Digital Health Tech Used in Clinical Investigations |
Sheppard, Mullin, Richter & Hampton LLP |
Apr 18 2014 |
Review – U.S. Patent and Trademark Office Subject Matter Eligibility Guidelines |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 5 2014 |
Now That That’s Settled: The Status of Class Action Settlements in the Seventh Circuit after Pella, Radioshack and NBTY |
Sheppard, Mullin, Richter & Hampton LLP |
Mar 17 2015 |
California Federal Court Finds that Class Action Plaintiffs’ False Advertising Claims are Stripped Bayer Based on Federal Preemption |
Sheppard, Mullin, Richter & Hampton LLP |
Dec 2 2022 |
Proposal to Overhaul Privacy Law Governing Substance Use Disorder Treatment Records |
Sheppard, Mullin, Richter & Hampton LLP |